{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:42:53Z","timestamp":1785598973683,"version":"3.56.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. The speed of development for mRNA and vector-based vaccines outpaced those of subunit vaccines, however, subunit vaccines can offer advantages in terms of safety and stability. Here we describe a subunit vaccine platform technology, the molecular clamp, in application to four viruses from divergent taxonomic families: Middle Eastern respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), Lassa virus (LASV) and Nipah virus (NiV). The clamp streamlines subunit antigen production by both stabilising the immunologically important prefusion epitopes of trimeric viral fusion proteins while enabling purification without target-specific reagents by acting as an affinity tag. Conformations for each viral antigen were confirmed by monoclonal antibody binding, size exclusion chromatography and electron microscopy. Notably, all four antigens tested remained stable over four weeks of incubation at 40\u00b0C. Of the four vaccines tested, a neutralising immune response was stimulated by clamp stabilised MERS-CoV spike, EBOV glycoprotein and NiV fusion protein. Only the clamp stabilised LASV glycoprotein precursor failed to elicit virus neutralising antibodies. MERS-CoV and EBOV vaccine candidates were both tested in animal models and found to provide protection against viral challenge.<\/jats:p>","DOI":"10.3389\/fimmu.2022.963023","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T07:15:45Z","timestamp":1660806945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["A platform technology for generating subunit vaccines against diverse viral pathogens"],"prefix":"10.3389","volume":"13","author":[{"given":"Andrew","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor A. P.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naphak","family":"Modhiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L. D.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey T. M.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalan","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S. M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayes K. H.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin-Hang","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna K. P.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C. Y.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Furuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Watterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30418-2","article-title":"The cost and challenge of vaccine development for emerging and emergent infectious diseases","volume":"6","author":"Maslow","year":"2018","journal-title":"Lancet Global Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701410114","article-title":"Emerging infectious diseases: A proactive approach","volume":"114","author":"Bloom","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5","article-title":"The covid-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","article-title":"Who issues its first emergency use validation for a covid-19 vaccine and emphasizes need for equitable global access who.int","volume-title":"World health organisation","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","article-title":"Chadox1 ncov-19 vaccine prevents sars-Cov-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mrna-1273 vaccine against sars-Cov-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1269","article-title":"Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Watterson","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the Chadox1 ncov-19 vaccine against sars-Cov-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two rna-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of ino-4800 DNA vaccine against sars-Cov-2: A preliminary report of an open-label, phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common features of enveloped viruses and implications for immunogen design for next-generation vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion mers-cov spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1950","article-title":"Distinct conformational states of hiv-1 Gp41 are recognized by neutralizing and non-neutralizing antibodies","volume":"17","author":"Frey","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01318-12","article-title":"Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins","volume":"86","author":"Chan","year":"2012","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz515","article-title":"A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal nipah virus and hendra virus infection","volume":"221","author":"Mire","year":"2020","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00584-8","article-title":"Broadly neutralizing antibody cocktails targeting nipah virus and hendra virus fusion glycoproteins","volume":"28","author":"Dang","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: Development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion hiv-1 env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.592370","article-title":"Rapid response subunit vaccine design in the absence of structural information","volume":"11","author":"Wijesundara","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41541-021-00395-4","article-title":"Development of molecular clamp stabilized hemagglutinin vaccines for influenza a viruses","volume":"6","author":"McMillan","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an Mf59-adjuvanted spike glycoprotein-clamp vaccine for sars-Cov-2: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.113","article-title":"A humanized neutralizing antibody against mers-cov targeting the receptor-binding domain of the spike protein","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for mers-cov neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/srep13133","article-title":"Structural basis for the neutralization of mers-cov by a human monoclonal antibody mers-27","volume":"5","author":"Yu","year":"2015","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix209","article-title":"Human neutralizing monoclonal antibody inhibition of middle East respiratory syndrome coronavirus replication in the common marmoset","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02002-17","article-title":"Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape","volume":"92","author":"Wang","year":"2018","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for mers-cov","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola Virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1912503116","article-title":"A structural basis for antibody-mediated neutralization of nipah virus reveals a site of vulnerability at the fusion glycoprotein apex","volume":"116","author":"Avanzato","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-019-0308-9","article-title":"An antibody against the f glycoprotein inhibits nipah and hendra virus infections","volume":"26","author":"Dang","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.027","article-title":"Recently identified mutations in the Ebola virus-makona genome do not alter pathogenicity in animal models","volume":"23","author":"Marzi","year":"2018","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1619109114","article-title":"Mouse-adapted mers coronavirus causes lethal lung disease in human Dpp4 knockin mice","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv499","article-title":"Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4","volume":"213","author":"Li","year":"2016","journal-title":"J Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1086\/515386","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"178","author":"Bray","year":"1998","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3920","article-title":"Vsv-ebov rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e52065","DOI":"10.3791\/52065","article-title":"Viral concentration determination through plaque assays: Using traditional and novel overlay systems","author":"Baer","year":"2014","journal-title":"J Vis Exp"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/srep41537","article-title":"Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine igg","volume":"7","author":"Pyankov","year":"2017","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4249","article-title":"Production of recombinant replication-defective lentiviruses bearing the sars-cov or sars-Cov-2 attachment spike glycoprotein and their application in receptor tropism and neutralisation assays","volume":"11","author":"Thakur","year":"2021","journal-title":"Bio Protoc"},{"key":"B52","doi-asserted-by":"publisher","first-page":":jgv001506","DOI":"10.1099\/jgv.0.001506","article-title":"Micro-fusion inhibition tests: Quantifying antibody neutralization of virus-mediated cell-cell fusion","volume":"102","author":"Thakur","year":"2021","journal-title":"J Gen Virol"},{"key":"B53","doi-asserted-by":"publisher","first-page":":1942","DOI":"10.3390\/v13101942","article-title":"Combinatorial f-G immunogens as nipah and respiratory syncytial virus vaccine candidates","volume":"13","author":"Isaacs","year":"2021","journal-title":"Viruses"},{"key":"B54","article-title":"Prioritizing diseases for research and development in emergency contexts who.int","volume-title":"World health organisation","year":"2020"},{"key":"B55","volume-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00842","article-title":"Structure-based design of nipah virus vaccines: A generalizable approach to paramyxovirus immunogen development","volume":"11","author":"Loomis","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir379","article-title":"Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection","author":"Tsuda","year":"2011","journal-title":"J Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.abg1208","article-title":"Development of unique Australian covid-19 vaccine halted","author":"Normile","year":"2020","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.5.12.3610-3616.1985","article-title":"Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product","volume":"5","author":"Evan","year":"1985","journal-title":"Mol Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1088-1204","article-title":"A short polypeptide marker sequence useful for recombinant protein identification and purification","volume":"6","author":"Hopp","year":"1988","journal-title":"Bio\/Technology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4155\/bio.10.31","article-title":"Immunoaffinity chromatography: An introduction to applications and recent developments","volume":"2","author":"Moser","year":"2010","journal-title":"Bioanalysis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080366","article-title":"Protein aggregation and bioprocessing","volume":"8","author":"Cromwell","year":"2006","journal-title":"AAPS J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13520","article-title":"Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months","volume":"7","author":"Pelliccia","year":"2016","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.05.002","article-title":"Lassa virus glycoprotein: Stopping a moving target","volume":"31","author":"Hastie","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.07.006","article-title":"A review of lassa fever vaccine candidates","volume":"37","author":"Salami","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00039-20","article-title":"A lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene","volume":"11","author":"Cai","year":"2020","journal-title":"mBio"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant lassa-rabies vaccine are critical for protection against lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2009.05.004","article-title":"Neutralizing ebolavirus: Structural insights into the envelope glycoprotein and antibodies targeted against it","volume":"19","author":"Lee","year":"2009","journal-title":"Curr Opin Struct Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":":71","DOI":"10.3390\/vaccines9020071","article-title":"Adjuvant selection for influenza and rsv prefusion subunit vaccines","volume":"9","author":"Isaacs","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B74","doi-asserted-by":"crossref","unstructured":"ExtanceA\n          Mrna vaccines: Hope beneath the hype thebmj2021","DOI":"10.1136\/bmj.n2744"},{"key":"B75","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mrna vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mrna vaccine against sars-Cov-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03275","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T07:15:51Z","timestamp":1660806951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2022.963023"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.963023","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"963023"}}